Last reviewed · How we verify
NCT05696990
3/7 Resistance Training Method in Cardiac Rehabilitation
NA trial testing 3/7 Resistance Training Method in Heart Failure in 112 participants. Completed in 30 August 2023.
1 March 2023
Quick facts
| Lead sponsor | Université Libre de Bruxelles |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 112 |
| Start date | 1 January 2019 |
| Primary completion | 1 March 2023 |
| Estimated completion | 30 August 2023 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- 3/7 Resistance Training Method
- 3X9 Resistance Training Method
Conditions studied
- Heart Failure — all drugs for Heart Failure →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Université Libre de Bruxelles — full company profile →
Who can join
18 and older, any sex, with Heart Failure or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of the clinical monocentric study is to assess the resistance training exercise intervention in patients with Heart Failure with reduced Ejection Fraction (HFrEF) and coronary artery disease that will best improve peak oxygen uptake (Peak Vo2) and leg strength (assessed Isokinetic). The investigators hypothesize that resistance training exercise with induced a high stress metabolic is more important exercise with induced than a lower stress metabolic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05696990
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Université Libre de Bruxelles trials
Trials by the same sponsor.
- NCT07568405 — The Effect of Remifentanil on the Objectively Measured Pressure Pain Threshold · NA · enrolling by invitation
- NCT07513974 — Objective Measurement of the Mechanical Pain Threshold With an Algometer for Predicting Intraoperative Opioid Consumptio · NA · recruiting
- NCT07236021 — e-Motion : Promoting Emotion Regulation in Chronic Cancer · NA · recruiting
- NCT06959069 — Impact of Intermittent Fasting on Sleep and Quality of Life · NA · recruiting
- NCT06666101 — Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05696990 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université Libre de Bruxelles
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05696990.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing